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Natural cutaneous anthrax infection, but
not vaccination, induces a CD4+ T cell response
involving diverse cytokines
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Abstract
Background: Whilst there have been a number of insights into the subsets of CD4+ T cells induced by pathogenic
Bacillus anthracis infections in animal models, how these findings relate to responses generated in naturally infected
and vaccinated humans has yet to be fully established. We describe the cytokine profile produced in response to
T cell stimulation with a previously defined immunodominant antigen of anthrax, lethal factor (LF), domain IV, in
cohorts of individuals with a history of cutaneous anthrax, compared with vaccinees receiving the U.K. licenced
Anthrax Vaccine Precipitated (AVP) vaccine.
Findings: We found that immunity following natural cutaneous infection was significantly different from that
seen after vaccination. AVP vaccination was found to result in a polarized IFNγ CD4+ T cell response, while the
individuals exposed to B. anthracis by natural infection mounted a broader cytokine response encompassing
IFNγ, IL-5, −9, −10, −13, −17, and −22.
Conclusions: Vaccines seeking to incorporate the robust, long-lasting, CD4 T cell immune responses observed in
naturally acquired cutaneous anthrax cases may need to elicit a similarly broad spectrum cellular immune response.
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Findings
Protective immunity against anthrax
Much research into protective, adaptive immunity against
bacterial pathogens has focused largely on the role of
neutralising antibodies. There is, however, growing inter-
est in the protective T cell immunity to bacterial infection
and the implications of this for rational vaccine design.
IL-17A, the hallmark cytokine of the Th17 subset, has
been demonstrated to be essential for protection in a
number of murine infection models [1]. Recently, it was
suggested that although both Th1 and Th17 responses
are generated by bacterial infection, the memory Th17
response is short-lived compared to the Th1 response [2].
In the case of Bacillus anthracis infection, murine models
suggest that protection against anthrax generated by an
inactivated spore vaccine is dependent on IFNγ release by
Th1 cells [3]. However, the extent to which these effector
phenotypes can be extrapolated to natural human infec-
tion remains poorly understood.
B. anthracis secretes three toxins, Protective Antigen
(PA) and two enzymatically active toxin subunits, Lethal
Factor (LF) and Edema Factor (EF), which together form
tripartite exotoxins, Lethal Toxin (LT) and Edema Toxin
(ET) [4]. The two vaccines currently licensed for use in
humans, the U.K.-licensed anthrax vaccine precipitated
(AVP) and the U.S.-licensed anthrax vaccine adsorbed
(AVA or Biothrax), are both derived from a filtered cul-
ture supernatant of B. anthracis strains [5-7], containing
variable amounts of these toxins. Whilst the presence of
PA specific toxin neutralizing antibodies is the primary
correlate of protection in current human vaccines, reli-
ance upon this antigen alone may limit the promotion of
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We previously demonstrated long-lived Th1 responses
in a cohort of individuals who had either recovered from
cutaneous anthrax or were exposed to anthrax toxin com-
ponents by vaccination [8,9]. Analysis of the cohort of
agricultural workers, previously infected with cutaneous
anthrax, showed robust CD4+ T cell memory to anthrax
antigens, in line with the observation that, though occupa-
tional exposure is ongoing, reinfection is rarely seen. Des-
pite the fact that the few studies which concern cellular
immunity to anthrax have concentrated primarily upon
analysing the T cell response to PA [10,11], it is known
that both PA and LF are capable of conferring protective
immunity in human and animal vaccination studies [4,12].
Protective immunity has been defined by the operational
criterion of neutralizing antibody titre, whereas the aim of
our work has been to clarify the adaptive immunity corre-
lates of long-term protection at the level of CD4 T cells in
survivors of natural exposure.
Our previous work showed that the T cell response to
Lethal Factor (LF) was focused upon domain IV [8], this is
the catalytic region of the protein and responsible for rapid
Mitogen-Activated Protein Kinase (MAPK) cleavage within
the host cell. The MAPK pathways are critical in control-
ling T cell activation and differentiation [13], and through
blocking the activation cascade, LT is capable of inhibiting
JNK, ERK and p38 mediated T cell proliferation [14,15].
Such inhibition is associated with the reduced production
of Th1 cytokines, IFNγ and TNFα, as well as the downreg-
ulation of the activation markers, CD69 and CD25 [15,16].
ET is capable of acting in a synergistic manner with LT
upon the MAPK pathways to suppress T cell chemotaxis in
response to CXCL12 [17], blocking the trafficking of both
naïve and effector memory T cells to infected tissues. In
combination with the elevation of intracellular cAMP by
ET, this has been reported to skew the differentiation of
naïve CD4+ T cells towards a Th2 subset, inhibiting activa-
tion of Akt1, a protein essential for the development of a
Th1 subset, whilst enhancing the activation of the guanine
nucleotide exchanger Vav1 and the stress kinase p38 which
are involved in Th2 differentiation [18]. Inhibition also im-
pacts on antigen presenting cells (APCs), reducing produc-
tion of both IFNγ by macrophages, and IL-12 by dendritic
cells (DCs) [19,20].
Conversely, recent work has suggested that exposure of
human ex vivo cells to ET at low concentrations is capable
of promoting a Th17 response [21], and studies in mice
have further indicated a key role for IL-17A in protective
immunity against inhalational anthrax [22,23]. Human
DCs have been found to respond to B. anthracis infection
by inducing a Th17 response characterised by IL-17 and
IFNγ production [24], thus suggesting the involvement of
these CD4+ T cells in a protective response. To evaluate
the nature of the immune response to B. anthracis anti-
gens, and specifically to investigate the possibility of
skewing towards certain Th subsets, we assessed cytokine
responses of CD4+ T cells against LF domain IV in natur-
ally infected and AVP vaccinated individuals.
Materials and methods
Study subjects
Human peripheral blood mononuclear cells (PBMC) were
collected from 9 individuals living in an endemic area of
Turkey who had a history of cutaneous anthrax within the
last 8 years, 10 volunteers from the UK routinely vaccinated
every 12 months for a minimum of 4.5 years with the U.K.
Anthrax Vaccine Precipitated (AVP) vaccine (U.K. Depart-
ment of Health) and 10 healthy controls from the UK with
no known exposure to anthrax antigens. Previous work has
shown that there is no demonstrable difference in healthy
controls from the UK and Turkey in terms of HLA or im-
mune cell population responses to anthrax antigens [25,8].
The study was approved by the appropriate ethics commit-
tees, (Ericyes University Ethical Committee, UK Depart-
ment of Health under approval by the Convention on
Biological Diversity Independent Ethics Committee for the
UK Ministry of Defence, and Ethics REC reference number
08/H0707/173), and was performed in accordance with the
1964 Declaration of Helsinki and its later amendments. All
participants gave their informed consent prior to inclusion
in the study.
Antigen stimulation
PBMCs were prepared from the sodium heparinised blood
using Accuspin tubes (Sigma-Aldrich) with Histopaque-
1077 and centrifuged at 800 g for 30 minutes, after which
cells were removed from the interface and washed twice
in AIM-V serum free media. Cells were counted for viabil-
ity and resuspended at 2x106 cells/ml, then stimulated for
72 h with 25 μg/ml of LF domain IV (which represented
the lowest concentration at which CD4+ responses could
be reproducibly obtained) or media only as a negative
control, in 96-well ELISpot plates, and the levels of IFNγ
produced by CD4+ T cells were determined in an ELISpot
assay as previously described [8]. Cell culture supernatants
were removed from the ELIspot assay at 72 h. All super-
natants were frozen at −80°C. Levels of IL-5, IL-9, IL-10,
IL-13, IL-17, and tumor necrosis factor alpha (TNFα)
were quantified following dilution 1:1 with AIM-V media.
The bead assay, based on a capture sandwich immuno-
assay method, was adapted from the manufacturer’s
protocol for a Bioplex assay (Bio-Rad). Briefly, a mixture
of antibodies to the cytokines, coupled to internally dyed
beads, were incubated with the samples and a standard
curve generated by serial dilution of reconstituted stand-
ard. The plates were washed twice with commercial Lumi-
nex wash buffer, and biotinylated detection antibodies
were added. Streptavidin-phycoerythrin was then added,
and the beads were read using the Luminex 200 system
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(Luminex Corporation). The individual dyed bead popu-
lations as well as the fluorescent signal on the bead sur-
face were detected. This allowed identification of each
cytokine and reported the level of target protein in the
well, extrapolated from the standard curve. IL-22 was
quantified by ELISA following manufacturer’s directions
(eBioscience), plates were read in a μQuant ELISA plate
reader (BIO-Tek Instruments Inc.) using KC Junior soft-
ware at a 450 nm wavelength with a reference wavelength
of 630 nm. The cytokine concentration in the samples
was extrapolated from the standard curve and expressed
for all cytokines as Δ pg/ml concentration (pg/ml cyto-
kine produced in response to LF domain IV - pg/ml cyto-
kine produced in response to negative control). Analyses
of the levels of each cytokine produced by the naturally
infected, AVP-vaccinated, and healthy control cohorts, in
response to the LF antigens, was compared using a two-
way ANOVA with Bonferroni post hoc testing. All statis-
tical analyses were determined by Kruskal Wallis with
Dunns multiple comparison test performed using Graph-
Pad Prism.
Results
Compared to non-infected, unvaccinated individuals, natur-
ally acquired cutaneous anthrax induced a diverse, CD4+ T
cell cytokine response, encompassing significant, antigen-
specific release of IFNγ (p < 0.001), TNFα (p < 0.001), IL-5
(p < 0.001), IL-9 (p < 0.001), IL-10 (p < 0.001), IL-13
(p = 0.045), IL-17 (p = 0.002) and IL-22 (p = 0.03) (Figure 1).
Thus, cutaneous anthrax induces a broad T cell memory
response characterized not only by the presence of Th1 cy-
tokines IFNγ and TNFα, but also Th2 (IL-5 and IL-13),
Th17 (IL-17/IL-22), Th22 (IL-22) and Th9 (IL-9) cytokines
and a potentially regulatory IL-10 response. In contrast to
the infection specific memory response to LF domain IV,
initial exposure to the same antigen in the context of the
AVP vaccine, led to a focused Th1 IFNγ response. Vacci-
nees show significantly more IFNγ (p = 0.002) than control
subjects (Figure 1), but no other cytokines were detected.
Discussion
Evidence from in vivo models and studies with cell lines
has given a somewhat equivocal picture of the cytokine re-
sponse to anthrax antigens. The inhibitory effects of both
LF and EF upon expression of the activation markers CD25
and CD69 and the secretion of the pro-inflammatory cyto-
kines IL-2, IL-5, TNFα, and IFNγ by human T cells has
been described in vitro [16,15]. Elevated transcription of
TNF-α, IL-1α, IL-1β, IL-4, IL-6, CCL5, CXCL2 and KC
have been observed in both murine anthrax challenge
models and in vitro macrophages and monocytic cell lines
exposed to anthrax antigens [26-30]. Conversely, murine
lymphocytes have shown impaired TCR mediated cell acti-
vation and selective suppression of the cytokines IL-2, IL-3,
IL-4, IL-5, IL-6, IL-10, IL-17, TNFα, IFNγ and GM-CSF
from CD4+ T cells following exposure to LF [14]. However,
the cellular immunity we have identified within the natur-
ally infected humans indicates that, although in vitro expos-
ure to anthrax antigens has been implicated in immune
deviation towards both the Th2 and Th17 pathways [31,18],
the human immune response to pathological anthrax ex-
posure encompasses a cytokine profile associated with a
broad range of Th subsets with little or no evidence of
helper T cell polarization. Indeed, following anthrax infec-
tion, in vitro recall responses to the LF domain IV protein
were characterised by a more diverse cytokine profile than
immunization with the AVP vaccine was capable of pro-
voking. The response to this immunogenic domain of LF
was dominated by IFNγ release in the vaccinees, whilst
the individuals exposed to LF following cutaneous anthrax
infection showed significantly elevated levels of the pro-
inflammatory cytokines in their in vitro recall response as-
sociated with Th1, Th2, Th9 and Th17 subsets, compared
to vaccinees and naïve controls. Previous work has sug-
gested that AVP vaccination has the capacity to lead to a
suppressed Th1 and Th2 response to LF and PA, relative
to the response mounted by naturally infected individuals
[8]. This is the first work to examine in detail the effect of
either encountering the antigen in the context of natural
infection or vaccination upon the cytokine profile pro-
voked by re-exposure to LF domain IV. Although this is
the first study, to our knowledge, to implicate IL-22 in the
host immune response against anthrax, recent analysis of
the role of IL-22 in Th17 mediated host immunity to bac-
teria at barrier surfaces [32], demonstrates the importance
of this cytokine in facilitating antimicrobial gene expres-
sion. In addition to the Th17 response, the known role of
IL-22 and IL-17 in promoting Th1 immunity to bacterial
pathogens [33] may play a crucial role in preventing the
survival of B. anthracis within the host. Conversely, survival
(See figure on previous page.)
Figure 1 Differential cytokine responses to anthrax LF domain IV following cutaneous infection or AVP vaccination. Cells from individuals exposed to LF
as a result of (▼) natural cutaneous infection (n = 8–9), or (▲) AVP vaccination (n = 8–10) and (■) unexposed healthy controls (n = 5-10) were stimulated
with 25 μg/ml of LF domain IV in vitro, and the cytokine profile of the supernatants assessed by either ELIspot, Luminex or ELISA. ELIspot results (A) are
expressed as the mean ΔSpot Forming Cells (SFC)/106 PBMCs (stimulated – unstimulated background level), while the ELISA and Luminex values are
given as the mean Δpg/ml detected for (B) TNFα, (C) IL-5, (D) IL-13, (E) IL-9, (F) IL-17, (G) IL-22 and (H) IL-10. * denotes a significantly greater cytokine
production in comparison to the unexposed controls (p≤ 0.05), as determined by Kruskal Wallis with Dunns multiple comparison test performed using
GraphPad Prism version 5.01 for Windows, GraphPad Software, La Jolla California USA.
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of B. anthracis in an unprotected host is dependent upon a
rapid suppression of Th1 cytokines [3]. Whilst we previ-
ously reported that the patient who developed toxemic
shock during B. anthracis infection showed the highest level
of IFNγ responses to both PA and LF [8], examining the el-
evated cytokine profiles in these patients did not reveal a
discernable trend related to either the period of time post
infection, the duration of infection or the clinical severity.
The marked difference noted between the infected indi-
viduals and vaccinees echoes the divergence in the epitope
repertoire recognised by each cohort. Whilst it might be ex-
pected that some epitopes present in the context of vaccin-
ation would be lost upon infection [34], the immune
response detected after AVP immunization differed sub-
stantially from that following infection [9,8]. It is unclear
whether this represents the differential antigen processing
of pathogen associated proteins experienced in vaccination
in contrast to infection, or if it represents an artefact of the
repeated AVP vaccinations which may have served to skew
the cytokine environment present during the induction of
the immune response, impacting upon the T cell epitope
repertoire [35]. Conversely, the difference both in the epi-
topes recognised and the nature of cytokine responses be-
tween the vaccinated and infected groups may relate to the
route of antigen exposure, as natural infection was localised
to the skin, in contrast to intra-muscular vaccination. In
the skin, bacterial antigens are processed and presented by
different subsets of dendritic cells [36], increasing the po-
tential for induction of a variety of Th responses. Alterna-
tively, the diversity of this response may represent the
complex interaction of the immune system with anthrax
toxins and a live, dividing bacterium where exposure dur-
ation is perhaps more prolonged. The divergence we de-
scribe in the immune response post-infection, compared to
vaccination, is not unprecedented; Mycobacterium tubercu-
losis infection results in high levels of mycobacteria-specific
IL-17 [37] and IL-9 [38] produced by T cells, whereas in re-
cent clinical trials of the MVA85A vaccine, only extremely
high doses induced a significant increase in IL-17 produc-
tion, despite prior BCG vaccination [39].
The human immune response to natural bacterial infec-
tion is often more complex than has been shown in murine
infection models and the existing vaccines are less well-
defined than recombinant sub-unit vaccines now in clinical
trial. It will be interesting to examine the T-cell responses in-
duced in human vaccines by these defined recombinant an-
thrax vaccines to determine if a cytokine profile associated
with protection from lethal anthrax infection is induced.
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